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738Objective: Current clinical trials are investigating the role of stereotactic body radiation therapy (SBRT) versus
sublobar resection for patients with non–small cell lung carcinoma (NSCLC) and marginal pulmonary function
tests (M-PFTs). We compared the outcomes of patients undergoing lobectomy with M-PFTs characterized by
2 accepted M-PFT criteria.
Methods: A total of 1,259 consecutive patients underwent lobectomy for NSCLC between 1999 and 2011.
Patients were stratified into 2 classifications of M-PFT: American College of Surgeons Oncology Group
(ACOSOG) Z4099/Radiation Therapy Oncology Group (RTOG) 1021 trial or American College of Chest
Physicians (ACCP) criteria. There were 206 patients classified as having M-PFT according to ACOSOG
Z4099/RTOG 1021 criteria and 131 patients classified as having M-PFT by ACCP criteria. The primary
endpoints of the study were post-operative complications and survival.
Results: Median follow-up was 3.8 years. Cox-proportional survival analysis found that pathologic stage
(P<.001), age (P<.001), and higher Zubrod functional status (P<.001) were independent predictors of mor-
tality. Using multivariable analysis for major morbidity, M-PFT status was not associated with the development
of a major complication following lobectomy (P¼ .68). M-PFT classification was not an independent predictor
of mortality when controlling for other variables (ACOSOG Z4099/RTOG 1021 [P ¼ .34]; ACCP criteria
[P ¼ .83]). A composite major morbidity analysis for major morbidity following lobectomy showed no associ-
ation between clinicopathologic variables or M-PFTs and the occurrence of a major postoperative morbidity.
Conclusions: In carefully selected patients with M-PFTs, lobectomy for NSCLC can be performed with
acceptable morbidity and mortality. These results need to be considered when deciding if a patient should
undergo lobectomy or other therapies for resectable NSCLC. (J Thorac Cardiovasc Surg 2014;147:738-46)Recent prospective clinical trials have investigated the use
of stereotactic body radiotherapy (SBRT) (Radiation
Therapy Oncology Group [RTOG] 0236), sublobar
resection (American College of Surgeons Oncology Group
[ACOSOG] Z4032), and radiofrequency ablation (RFA)
(ACOSOG Z4033) for early stage non–small cell lung car-
cinoma (NSCLC) for patients who have been considered
medically inoperable or at high-risk for surgical interven-
tion.1 Although results for ACOSOG Z4032 and ACOSOG
Z4033 have not been published to date, the phase II trial of
SBRT (ie, RTOG 0236) demonstrated a 3-year overall
survival of 56% and disease-free survival of 48% for
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The Journal of Thoracic and Cardiovascular Surgresulted in the randomized clinical trial (ie, ACOSOG
Z4099/RTOG 1021) comparing SBRT to sublobar resection
in high-risk patients with stage I disease based on marginal
pulmonary function tests (M-PFTs) and comorbidities.
Although interest in SBRTand sublobar resection for early
stage NSCLC in high-risk patients has grown over the past
10 years, the current gold standard therapy for NSCLC is lo-
bectomy. Ginsberg and colleagues3 previously demonstrated
a 3-fold increase in locoregional recurrences in patients with
T1N0 disease undergoing wedge resection or segmentec-
tomy. In a retrospective analysis,4 we showed that sublobar
resection is associated with a 4-fold increase in locoregional
recurrence after R0 resection. Additionally, some patients
with M-PFTs have centrally located tumors or larger tumors
and lobectomy is often required to obtain an R0 resection.
We investigated the outcomes of patients undergoing
lobectomy for NSCLC classified as high risk for surgery
using both the inclusion criteria for the ACOSOG Z4099/
RTOG 1021 trial and American College of Chest Physicians
(ACCP) criteria.
METHODS
Patient Selection
A retrospective analysis of a prospectively maintainedGeneral Thoracic
Surgery Database at the University of Virginia from July 1999 throughery c February 2014
Abbreviations and Acronyms
ACCP ¼ American College of Chest Physicians
ACSOG¼American College of Surgeons Oncology
Group
CT ¼ computed tomography
DLCO ¼ diffusing capacity for carbon monoxide
FEV1 ¼ forced expiratory volume in 1 second
M-PFT ¼ marginal pulmonary function test
NSCLC ¼ non–small cell lung carcinoma
RFA ¼ radiofrequency ablation
RTOG ¼ Radiation Therapy Oncology Group
SBRT ¼ stereotactic body radiotherapy
STS ¼ The Society of Thoracic Surgeons
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SAugust 2011 was performed. The General Thoracic Surgery Database is
maintained by the Division of Thoracic and Cardiovascular Surgery and
includes all data fields contained within the Society of Thoracic Surgeons
(STS) General Thoracic Surgery Database in addition to other important
clinicopathologic variables. All standardized variables analyzed represent
STS definitions. Clinicopathologic variables were selected a priori and
included age, sex, pathologic stage, Zubrod function status, hypertension,
coronary artery disease, peripheral vascular disease, diabetes (requiring
hypoglycemic medications), M-PFT status, and need for home oxygen
therapy (continuous or nocturnal). The Human Investigations Committee
at the University of Virginia approved this study.
A study population of 1259 patients who underwent a lobectomy for
NSCLCwas selected for analysis. Patients with carcinoid histology, second
lung primary lesions, and sublobar resection were excluded from the study.
The majority of patients had clinical stage I NSCLC. Pathology reports
were staged using the seventh edition of the American Joint Cancer
Committee/Union Internationale Contre le Cancer criteria. Post-
operatively, patients were initially seen at 2 to 3 weeks by the thoracic
surgeon, and then again every 6 months following resection with
contrast-enhanced chest computed tomography (CT) for 5 years.
Subsequent to this visit, either a chest roentgenogram or CT of the chest
was reviewed annually. Positron emission tomographywith CTormagnetic
resonance imaging was used as clinically warranted. All visits were
completed in concert with the referring oncologist when indicated. The
primary outcome of interest was to examine postoperative complications
and survival in patients with M-PFTs compared with patients with
non–M-PFTs following lobectomy for NSCLC.
Classification and Calculation of M-PFT
All patients had pulmonary spirometry performed with measurement of
forced vital capacity, forced expiratory volume in 1 second (FEV1), and
diffusing capacity for carbon monoxide (DLCO). Patients were stratified
into two M-PFT categories: ACOSOG Z4099/RTOG 1021 randomized
trial for SBRT versus sublobar resection (FEV1 50% or DLCO 50%
or age >75 years and FEV1 50%-60% or age >75 years and
DLCO 50%-60%) and ACCP criteria (postoperative FEV1 <40% or
postoperative DLCO <40%). Although the majority of patients had
pre-resection quantitative perfusion scans, not all patients did. Therefore,
for the purposes of this study the post-resectional corrected postoperative
FEV1 and postoperative DLCO were calculated based on the remaining
bronchopulmonary segments following lobectomy.
Composite Major Morbidity Model
To compare the likelihood of a major postoperative morbidity in
patients undergoing lobectomy for NSCLC, we created a composite majorThe Journal of Thoracic and Camorbidity model that would define associations between clinicopathologic
variables and the postoperative occurrence of at least 1 major morbidity.
We performed 2 separate statistical analyses investigating the composite
major morbidity model using the entire cohort based upon separate
M-PFT definitions. The first analysis investigated the composite major
morbidity model of patients using the ACOSOG Z4099/RTOG 1021 trial
definition included 206 patients with M-PFT and 1053 patients with
non–M-PFTs. The second analysis of composite major morbidity used
the ACCP M-PFT definition and included 131 patients with M-PFT and
1128 patient with non–M-PFTs. The complications included in the model
were postoperative pneumonia, myocardial infarction, reintubation, renal
failure, and atrial arrhythmia. The risk-adjusted composite major morbidity
and the association with clinicopathologic variables were assessed using
Cox-proportional hazards regression analysis.
Statistical Analysis
The effect of PFT status on patient short-term and long-term outcomes
was assessed using standard hypothesis testing statistical analyses.
Categorical variables are presented as a percentage of the group of origin,
whereas continuous variables are presented as mean  standard deviation
(for normally distributed data) or median (interquartile range)
(for non-normally distributed data). Descriptive and unadjusted differences
between marginal and non-marginal study cohorts were determined using
the c2 or Fisher exact test for categorical variable comparisons, whereas
single-factor analysis of variance or the Mann Whitney U test were used
to compare continuous data where appropriate.
The effect of PFT status on overall survival was assessed using
unadjusted and risk-adjusted survival analyses. Two separate statistical
analyses investigating overall survival were performed for all patients
included in the study based upon separate M-PFT definitions. The first
analysis investigated the overall survival of patients using the ACOSOG
Z4099/RTOG 1021 trial definition, which included 206 patients with
M-PFTs and 1053 patients with non–M-PFTs. The second analysis of
overall survival used the ACCP M-PFT definition and included 131
patients with M-PFTs and 1128 patient with non–M-PFTs. The unadjusted
relationship between PFT status and survival was assessed using
Kaplan-Meier analysis with the log-rank test, whereas risk-adjusted
survival differences as a function of PFT status were assed using
Cox-proportional hazards regression analysis.
Calculated test statistics were used to determine all probability
estimates, and standard statistical significance was set to a < 0.05.
All statistical analyses were performed using PASW version 19.0.0
(IBM Corp, Armonk, NY).
RESULTS
The demographic characteristics of the populations
investigated are shown in Table 1. Using ACOSOG
Z4099/RTOG 1021 M-PFT criteria, 206 patients were
classified as having M-PFTs. With ACCP M-PFT criteria,
131 patients were classified as having M-PFTs. The mean
age of patients and sex distribution with M-PFTs were not
significantly different compared with the non-marginal
group in both categories. Of all patients within the study,
6.1% had induction therapy before resection. Both
M-PFT categories had equal proportions of both upper
and lower lobectomies. Middle lobectomies were more
common in both categories of M-PFTs compared with
patients with non–M-PFTs. There was no significant
difference in the proportion of pathologic stages between
both categories of M-PFT compared with patients with
non–M-PFTs. The proportion of M-PFT patients with ardiovascular Surgery c Volume 147, Number 2 739
TABLE 1. Patient demographics
Variable
ACOSOG Z4099/RTOG 1021 M-PFT criteria (n ¼ 1259) ACCP M-PFT criteria (n ¼ 1259)
M-PFTs
(n ¼ 206)
Non–M-PFTs
(n ¼ 1053) P
M-PFTs
(n ¼ 131)
Non–M-PFTs
(n ¼ 1128) P
Age, y (mean  standard deviation) 69.4  9.6 66.8  10.5 .34 66.4  9.7 66.0  10.1 .48
Sex (men:women) 104:102 507:546 .57 65:68 538:588 .92
FEV1,% (median [range]) 64 (15-136) 84 (51-169) .001 57 (15-120) 77 (45-169) .001
DLCO,% (median [range]) 49 (13-141) 79 (51-156) .001 48 (13-102) 81 (48-156) .001
FVC,% (median [range]) 77 (22-140) 89 (52-151) .001 69 (22-137) 89 (43-151) .001
Median length of stay, d 6.2 5.4 .78 6.4 5.1 .67
Tumor location
Upper lobe 138 (66.9) 698 (66.2) .95 93 (70.7) 743 (65.9) .20
Middle lobe 16 (7.9) 41 (3.9) .04 14 (10.5) 43 (3.8) .001
Lower lobe 52 (25.2) 314 (29.9) .23 26 (19.8) 340 (30.3) .17
Pathologic stage
I 141 (66.5) 702 (64.9) .69 84 (64.4) 759 (66.9) .49
II 46 (21.6) 217 (20.0) .58 30 (22.8) 233 (20.3) .57
III 16 (10.5) 118 (13.6) .22 15 (11.5) 119 (11.0) .76
IV 3 (1.4) 16 (1.5) 1.0 3 (2.3) 16 (1.8) .43
Comorbidities
Hypertension 56 (27.3) 246 (23.4) .25 34 (26.3) 268 (23.7) .59
Coronary artery disease 39 (19.3) 210 (20.0) .74 27 (20.3) 222 (19.6) .82
Peripheral vascular disease 62 (5.9) 99 (9.4) .65 10 (7.5) 151 (13.4) .07
Diabetes 21 (10.1) 140 (13.3) .20 12 (9.5) 149 (13.2) .21
Zubrod functional status>1 27 (13.1) 69 (6.5) .001 15 (11.3) 81 (7.2) .08
Home oxygen therapy 22 (10.7) 37 (3.5) .001 12 (9.5) 47 (4.2) .01
Postoperative complications
30-d mortality,% 0.5 1.4 .10 0.8 1.3 .09
Pneumonia,% 10.4 5.6 .002 10.6 5.8 .01
Re-intubation,% 5.3 1.1 .62 4.6 3.7 .44
Myocardial infarction,% 2.7 0.7 .008 2.3 0.8 .01
Acute renal failure,% 2.8 0.7 .01 2.3 0.8 .01
Supraventricular arrhythmia,% 12.4 9.3 .16 13.7 9.4 .06
Values are presented as n (%) unless otherwise noted. ACOSOG, American College of Surgeons of Oncology; RTOG, Radiation Therapy Oncology Group; M-PFT, marginal
pulmonary function test; ACCP, American College of Chest Physicians; FEV1, forced expiratory volume at 1 second; DLCO, carbon monoxide diffusing capacity; FVC, forced
vital capacity.
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patients with non–M-PFTs (13.1% vs 6.5%; P ¼ .001).
Additionally, a larger proportion of patients with M-PFT
required home oxygen before surgery (10.3% vs 3.5%).
There was no significant difference in 30-day mortality
in both M-PFT classifications when compared with
non–M-PFT patients. The M-PFT group had a higher
90-day mortality compared with non–M-PFT patients
(3.8% vs 2.6%) but did not reach statistical significance
(P ¼ .15). The incidence of preoperative renal dysfunction
was not significantly different between patients with
M-PFTs and those patients with non–M-PFTs (ACOSOG
Z4099/RTOG 1021 criteria P ¼ .67, ACCP criteria
P ¼ .73). Both M-PFT categories were associated
with a higher incidence of postoperative pneumonia,
myocardial infarction, and acute renal failure compared
with non–M-PFT patients.
Table 2 illustrates the multivariable analysis comparing
overall survival between patients with M-PFTs and740 The Journal of Thoracic and Cardiovascular Surgnon–M-PFTs. In both M-PFT categories, pathologic stage,
age, and Zubrod status were all associated with decreased
overall survival. Pathologic stage was the variable with
the strongest association to overall survival (Wald test,
35.70 and 36.42) whereas M-PFT status was not associated
with overall survival. Preoperative radiation therapy was
associated with a significant decrease in overall survival
(P ¼ .04). We found there was no significant difference in
overall survival when comparing patients who underwent
upper lobectomy to those who underwent lower lobectomy
(4.3 vs 4.9 years, respectively; P¼ .93). Figure 1 illustrates
the risk-adjusted overall survival curves for both categories
of M-PFT classifications. In both M-PFT categories,
M-PFTs were not associated with a decrease in overall
survival compared with patients with non-marginal PFTs.
We then created a composite major morbidity model
(Table 3) that included postoperative pneumonia,
myocardial infarction, reintubation, acute renal failure,
and supraventricular tachycardia to determine whatery c February 2014
TABLE 2. Multivariable analysis for overall survival
Variable
ACOSOG Z4099/RTOG 1021 M-PFT criteria (n ¼ 1259) ACCP M-PFT criteria (n ¼ 1259)
Wald P HR Wald P HR
Pathologic stage* 35.70 <.001 36.42 <.001
IB 2.52 .11 1.20 2.56 .11 1.20
IIA 0.194 .66 0.92 0.42 .52 0.88
IIB 2.06 .15 1.25 2.08 .15 1.25
IIIA 14.80 <.001 1.81 14.00 <.001 1.79
IIIB 19.08 <.001 2.34 19.70 <.001 2.38
IV 6.88 .009 2.38 7.05 .008 2.42
Age 34.64 <.001 1.03 33.47 <.001 1.03
Zubrod statusy 23.60 <.001 24.50 <.001
1 10.23 .001 1.37 12.29 <.001 1.41
2 16.55 <.001 2.02 15.87 <.001 2.01
3 4.93 .03 2.38 4.96 .03 2.38
Hypertension 3.86 .05 0.77 3.14 .08 0.79
Coronary artery disease 2.27 .13 1.20 2.29 .13 1.20
Peripheral vascular disease 1.42 .23 1.28 1.13 .29 1.24
Sex (female) 1.32 .25 0.90 1.67 .20 0.89
Diabetes 1.26 .26 1.17 0.71 .40 1.13
M-PFT status 0.91 .34 1.12 0.48 .83 0.97
Home oxygen therapy 0.47 .49 0.84 0.53 .46 0.83
ACOSOG, American College of Surgeons of Oncology; RTOG, Radiation Therapy Oncology Group; M-PFT, marginal pulmonary function test; ACCP, American College of
Chest Physicians; HR, hazard ratio. *Reference stage: 1A. yReference: 0.
Taylor et al General Thoracic Surgeryclinicopathologic variables may be associated with the
occurrence of at least 1 major complication following
lobectomy. There was no significant difference in the
incidence of major postoperative morbidity on univariateFIGURE 1. A, Risk-adjusted overall survival curve for American College of S
trial or American College of Chest Physicians (ACCP) marginal-pulmonary fu
ACCP M-PFT criteria.
The Journal of Thoracic and Caanalysis when comparing patients who underwent upper
lobectomy to lower lobectomy (P ¼ .52). A multivariable
analysis was conducted using this morbidity model. The
only variable associated with a major complication wasurgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021
nction test (M-PFIT) criteria. B, Risk-adjusted overall survival curve for
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TABLE 3. Multivariable analysis for composite morbidity model
Variable
ACOSOG Z4099/RTOG 1021 M-PFT criteria (n ¼ 1259) ACCP M-PFT criteria (n ¼ 1259)
Wald P HR Wald P HR
Pathologic stage* 3.61 .73 4.72 .58
IB 0.44 .51 1.14 0.05 .83 1.04
IIA 0.37 .54 0.83 1.09 .30 0.72
IIB 0.009 .92 1.03 0.02 .89 1.04
IIIA 0.12 .73 1.10 0.23 .63 1.14
IIIB 0.02 .88 0.96 0.03 .86 0.95
IV 2.40 .12 2.54 2.97 .08 2.86
Age 5.10 .02 1.02 2.50 .11 1.01
Zubrod statusy 5.10 .16 5.09 .17
1 2.67 .10 0.76 3.44 .06 0.73
2 0.52 .47 1.19 0.18 .67 1.11
3 0.21 .65 1.27 0.10 .76 1.18
Hypertension 0.51 .48 1.14 0.17 .68 1.08
Coronary artery disease 0.19 .66 1.09 0.19 .66 1.09
Peripheral vascular disease 2.20 .14 0.66 0.72 .40 0.79
Sex (female) 0.01 .91 0.98 0.10 .76 0.95
Diabetes 1.14 .29 0.78 1.46 .23 0.75
M-PFT status 0.17 .68 0.93 2.23 .14 0.65
Home oxygen therapy 1.00 .32 1.31 3.42 .06 1.65
ACOSOG, American College of Surgeons of Oncology; RTOG, Radiation Therapy Oncology Group; M-PFT, marginal pulmonary function test; ACCP, American College of
Chest Physicians; HR, hazard ratio. *Reference stage: 1A. yReference: 0.
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criteria for M-PFTs. Neither M-PFT classification was
associated with an increased risk of developing any of
the 5 complications included in the composite model.
Additionally, we found that current smoking status and
induction therapy were not associated with an increased
risk of a major complication postoperatively (P ¼ .65 and
.81, respectively).
DISCUSSION
This study demonstrates that M-PFTs, as classified by 2
methodologies, are not associated with a decrease in overall
survival in patients undergoing lobectomy for NSCLC.
Also, when risk-adjusting for preoperative and pathologic
variables, the incidence of significant morbidity was not
greater in selected patients with M-PFTs who underwent
lobectomy.
Currently, the standard resectional strategy for patients
with NSCLC who have adequate pulmonary reserve and
are deemed low to moderate risk for surgery is lobectomy.
For patients considered medically inoperable or at high
risk for surgery, sublobar resection, brachytherapy/wedge
resection, SBRT, and RFA have all been proposed as
alternative treatment strategies. Previous studies have
demonstrated an increased incidence of locoregional
recurrence following sublobar resection compared with
lobectomy.3-6 Comparison of oncologic outcomes
between sublobar resection and lobectomy will be
elucidated with the results of the Cancer and Leukemia
Group B 140503 trial.742 The Journal of Thoracic and Cardiovascular SurgRobinson and colleagues7 compared the outcomes of
patients with stage I NSCLC undergoing lobectomy or
pneumonectomy versus SBRT in 338 patients. Patients
who underwent SBRT in this study had median FEV1 of
51% compared with patients who underwent lobar
resection with a median FEV1 of 79% (P < .0001).
DLCO was significant lower in the SBRT group versus
lobar resection group (62% vs 79%; P ¼ .001). In this
comparison, 4-year local control was 99% for the surgical
arm versus 94% in the SBRT arm, which was not
significantly different. Overall survival favored lobar
resection (64% vs 30%) but disease-specific survival was
not significant between groups. The difficulty with this
analysis is that the 2 populations studied are inherently
different based on pulmonary function, comorbid
conditions, and tumor size.
Results from RFA studies for stage I NSCLC have
demonstrated an overall 2-year survival rate between
68% and 72%.8,9 However, these studies demonstrated
significant locoregional failure rates associated with RFA.
Pennathur and colleagues8 showed 42% locoregional
failure at 27 months from RFA treatment in patients with
a median FEV1 of 29%. In addition, Lanuti and colleagues9
showed an 80% locoregional failure rate following RFA
for tumors>3 cm in size in patients with a mean FEV1 of
62%.
Use of current marginal PFT criteria as a sole means to
exclude patients from definitive resection and for inclusion
in studies for alternative therapies such as SBRT, RFA,
or sublobar resection are not supported by our findings.ery c February 2014
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M-PFT classifications suggests that the criteria for a
high-risk surgical candidate within SBRT trials may not
be strict enough and a significant proportion of patients
undergoing SBRT could in fact tolerate a lobectomy.
We chose to limit our study to patients with M-PFTs who
underwent lobectomy. Previous studies have investigated
the predictive ability of pulmonary function tests on
outcomes following lobectomy. Berry and colleagues10
evaluated the predictors of pulmonary complications in
340 patients with a FEV1 or DLCO of 60% or less who
underwent thoracoscopy (n ¼ 173) or thoracotomy
(n ¼ 164) and subsequent lobectomy. DLCO and FEV1
were found to be predictors of pulmonary complications
in patients undergoing thoracotomy but not thoracoscopy.
Both M-PFT criteria used in our study were stricter than
that study. Several studies show the incidence of pulmonary
complications and mortality are acceptable in patients
undergoing lobectomy with postoperative pulmonary
function <50% predicted.11,12 Puente-Maestu and
colleagues13 developed an algorithm using postoperative
predicted peak oxygen uptake>10 mL/kg/minute to assess
suitability for surgery in patients with postoperative FEV1
and/or postoperative DLCO <40%. When comparing
patients with postoperative FEV1 and postoperative
DLCO>40% to patients with postoperative FEV1 and/or
postoperative DLCO <40%, overall survival at 2 years
was not significantly different between groups (71% vs
57%; P ¼ .15). Sixty-day mortality was 6.5% in patients
undergoing lobectomy and 2-year overall survival was
66%.
Previous studies have investigated the association of
preoperative variables on outcomes following lung cancer
resection. Kozower and colleagues14 used the STS General
Thoracic Surgery Database to define predictors of
morbidity and mortality following lung cancer resection.
Several variables were found to be predictors of mortality,
including increasing Zubrod score, increasing age, and
decreasing FEV1. Our study also found that increasing
age and increasing Zubrod functional status was associated
with an increase in mortality following lung cancer
resection. Several differences exist between this study and
the study published by our group previously. First, this
study included only patients undergoing lobectomy,
whereas the previous study also included patients
undergoing pneumonectomy and sublobar resection.
Second, the STS database is not internally audited for
data quality, whereas our database is audited. Third, the
STS database is limited to 30-day follow-up, whereas our
study had a median follow-up of 3.8 years. Wright and
colleagues15 also demonstrated that increasing age, Zubrod
score, and decreased FEV1 were predictors of prolonged
length of stay following lobectomy for lung cancer using
the STS database. Length of stay was not statisticallyThe Journal of Thoracic and Cadifferent between patients with M-PFTs compared with
patients with non–M-PFTs in our study.
Our study demonstrates that classification of patients as
having M-PFTs does not predict mortality or major
morbidity following lobectomy. Our 30-day perioperative
mortality rates for both M-PFT groups was<1%. Although
the multivariable analysis of composite morbidity showed
no association with the incidence of 1 major morbidity
and M-PFT status, we did find a 4-fold increase in
postoperative myocardial infarction and acute renal failure
in the M-PFT group. This discovery may lead to changes in
practice guidelines for patients with M-PFTs. In patients
with M-PFTs who do not have identifiable risk factors for
coronary artery disease, preoperative cardiac stress testing
may be warranted to identify patients who may benefit
from preoperative coronary revascularization or medical
optimization before surgery. Despite no significant
difference in baseline creatinine levels between M-PFT
and non–M-PFT groups, M-PFT patients had a 4-fold
higher incidence of acute renal insufficiency compared
with non–M-PFT patients. This finding suggests that the
potential need for judicious fluid management in the
postoperative period may be resulting in hypovolemia and
subsequent renal insufficiency. However, further studies
investigating the need for renal protective strategies are
needed inM-PFT patients. Future studies should investigate
the minimal post-resection pulmonary function needed to
avoid postoperative respiratory failure with associated
morbidity and mortality taking into account the use of
minimally invasive techniques, perioperative epidural
catheter use, and optimization of pulmonary physiotherapy
in the postoperative period.
The limitations of this study include the retrospective
nature of the analysis and the possibility for selection
bias. Another limitation is that our patients did not routinely
undergo baseline arterial blood gas analysis, mixed venous
partial pressure of oxygen testing, or echocardiogram to
assess pulmonary hypertension before surgery. Therefore,
we were unable to capture additional patients who would
have been considered to have M-PFTs according to the
ACOSOG Z4099/RTOG 1021 trial definitions.
CONCLUSIONS
M-PFTs, as classified by 2methodologies currently being
evaluated in clinical trials, are not associated with a
decrease in overall survival in patients undergoing
lobectomy for NSCLC. Additionally, when controlling for
preoperative and pathologic variables, the incidence of
having any significant morbidity following surgery was
not greater in patients with M-PFTs undergoing lobectomy.
This study suggests that current SBRT and sublobar
resection trials characterizing patients as nonsurgical
candidates based on 2 accepted M-PFT definitions may be
excluding patients from undergoing lobectomy, the currentrdiovascular Surgery c Volume 147, Number 2 743
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needed to ascertain the influence of other patient factors
used my experienced thoracic surgeons in determining the
candidacy for lobar resection in patients with marginal
pulmonary reserve.
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Dr Yolonda L. Colson (Boston, Mass). I want to commend you
on a very nice presentation. We have seen several presentations at
this conference that are investigating surgical resection in marginal744 The Journal of Thoracic and Cardiovascular Surgpatients, reflecting how important this topic really is and that we
face it regularly.
I have 3 questions to look at your analysis in more depth.
In the non-marginal group you have almost a 5% incidence of
re-intubation. That seems unusually high. Does it affect the fact
that you say there wasn’t much difference in complications if the
higher incidence of complications was in the non-marginal group?
Among the complications that you did have, did you look at
length of stay, for example, and what the ramifications of those
complications were?
Dr Taylor. Thank you for your questions. There was a
re-intubation rate within the non-marginal pulmonary function
test (PFT) group of approximately 5.3% versus 1.1% in the
marginal PFT group. However, this difference was not
found to be statistically different on univariate analysis. It
is not clear why the non-marginal group had a 4% higher
re-intubation rate. It may be that we are more conservative
in extubating patients with marginal PFTs because of concern
for re-intubation. We did not include length of stay analysis
or specific analysis of the ramifications of postoperative
complications. I think it is important to note that on our
univariate analysis there was a significant difference in a
number of variables, including postoperative myocardial
infarction and acute renal failure. Despite the fact that we
found no significant associations on multivariable analysis,
this data may provide important information about patients
who have marginal PFTs and the need for additional preoper-
ative risk assessment.
Dr Colson. In patients with marginal PFTs, we usually choose
stereotactic body radiotherapy or some other ablative type of
therapy. They tend to think more about quality of life issues or
what the complications are, and that is often the reason that these
therapies will get chosen, more so necessarily than mortality.
In your presentation, we don’t really see afterward what the
functional status is of patients who have had a lobectomy and
how many of them were not receiving oxygen before and then
became oxygen dependent. What is the change that happened
other than just survival and a complication? What happened to
them in terms of their quality of life?
Dr Taylor. That is a great question. I agree that quality of life in
the marginal PFT patient population is quite important. However,
we have not performed quality-of-life assessments on patients
included in this study. That information would be a great follow-up
study.
Dr Colson. We know if you do a lobectomy on a patient
who has an upper lobe with a large bullous emphysema or a
middle lobectomy it is very different than doing a lower
lobectomy on somebody who has significant perfusion to that
lobe, and I don’t see that broken out here. Can you characterize
what characteristics in these marginal patients allow safe
resection? Who did well and didn’t do well in terms of what their
disease looked like?
Dr Taylor. Looking at the demographics of the population,
there was no difference in the proportion of upper lobectomy to
lower lobectomy when comparing marginal group to nonmarginal
group. We did not perform a subgroup analysis to determine, for
example, what factors are important for a good outcome in patients
with marginal PFTs who underwent lower lobectomy. This is aery c February 2014
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be important to consider in patients with marginal PFTS who
need resection.
Dr Colson. Is it possible that what we are really looking at is
that these results confirm the ability of a surgeon to look at
marginal PFTs and decide when they are not as marginal as we
think?
Dr Taylor. That is a great point. Pulmonary function tests are
only 1 factor in considering if a patient is eligible for resection
and it is clear that a thorough evaluation of the entire clinical
picture is essential when considering lobectomy in this patient
population.
Dr Thomas A. D’Amico (Durham, NC). I enjoyed your
presentation, Dr Taylor.
What percentage of the patients underwent thoracoscopic
lobectomy?
Dr Taylor. Thoracoscopic lobectomy represented 20% of the
procedures performed.
DrD’Amico.Did you not put that in your risk model, whether it
was a thoracoscopic or open lobectomy?
Dr Taylor. Given the small proportion of patients undergoing
video-assisted thoracoscopic lobectomy, we did not include it.
We did do a subgroup analysis that is not included in the results
reported here and we did not find any significant difference
between video-assisted thoracoscopic surgery and the open
technique with regard to morbidity and mortality in patients with
marginal PFTs. Now, if that is a reflection of our sample size
and the fact that we have significantly fewer patients who
underwent video-assisted thoracoscopic surgical procedures than
open, that may be the case.
Dr D’Amico. Do you have any idea what percentage had
pulmonary hypertension?
Dr Taylor. I do not have the percentage of patients within
the study who have pulmonary hypertension. I believe that is
1 of the limitations of this study. Not having pulmonary
hypertension data limits some of the inclusion criteria within the
clinical trial.
Dr K. Robert Shen (Rochester, Minn). I enjoyed your
presentation very much and I think it is a very timely analysis.
One of the things that all thoracic surgeons do when
evaluating if patients with marginal pulmonary function can
tolerate surgery is to factor in other things that we inherently
know will affect that patient’s risk profile. Although there isn’t
much prospective data to prove that getting current smokers to
stop smoking for a period of time before surgery and putting
them through a preoperative pulmonary rehabilitation program
has a positive effect in getting a patient with marginal PFT
through an operation safely, I am more inclined in that patient
compared with a patient with good PFT, to say, ‘‘I’m not going
to offer you surgery until you stop smoking and go through
pulmonary rehab.’’ Did you put into your risk model any
information about whether or not those patients in the
marginal group were treated differently in terms of things like
that—requiring them to stop smoking, putting them through
rehab—and does the data allow you to address any of those
issues? I think they are quite important and we are
lacking data to show if those things may be helpful in these
patients.The Journal of Thoracic and CaDr Taylor.We did not include those particular variables within
our analysis. There are data that suggest that pulmonary rehab is
effective for increasing exercise capacity, but there is some
question as to whether there is any increase in actual PFT
improvement. I agree that evaluating the effect of smoking
cessation and the use of pulmonary rehab on patients with
marginal PFTs may uncover another variable that may be
important in risk stratifying this patient population.
Dr Raphael Bueno (Boston, Mass). Do you have 90-day
mortality data? Particularly for these kinds of patients, we ought
to start reporting 90-day mortality.
Dr Taylor. In the non-marginal group, our 90-day mortality was
2.6% and in the marginal group it was 3.8%.
Dr Bueno. So that is substantially up from 30-day mortality.
Dr Taylor. That is correct. It was not statistically significant on
univariate analysis.
Dr Bueno. So, again, reinforcing the need to answer that
question.
Dr Thomas K.Waddell (Toronto, Ontario, Canada). I enjoyed
your presentation.
I am convinced by your data that the current criteria by which
these trials have been constructed are not good predictors. I think
that is pretty obvious. The question is if there are better predictors.
I think there are 2 subsets of things you should consider. How
many patients went on to stereotactic body radiation therapy and
what did their profile look like by these same measures; that is,
do you actually just use a lower threshold of the same measures,
or are you not measuring to these criteria and not based on the
right measure? I am interested in to what extent these marginal
candidates had mixed venous partial pressure of oxygen
measurements, forced vital capacity measurements to really
determine that forced expiratory volume in 1 second below a
certain level is actually an obstructive physiology, and quantitative
ventilation/perfusion lung scan, so just in general, the use of
ancillary measures to more precisely refine your patient selection.
Dr Taylor. Thank you Dr Waddell for these important
questions. Although we did not include the profile of patients
undergoing stereotactic body radiation therapy within our
institution in this study, I believe your point is critical and a
comparison that needs to be evaluated. With regard to our use
of ancillary measures to further define pulmonary function
(ie, quantitative perfusion scan and mixed venous partial pressure
of oxygen), our algorithm is that if a patient has an forced
expiratory volume in 1 second or carbon monoxide diffusing
capacity<50%, then we proceed with a quantitative perfusion
scan. If that is<40%, then we will proceed with an mixed venous
partial pressure of oxygen study. If it is>15, we consider them
eligible for resection. If the value is between 10 and 15, it is a
discussion between all parties involved, including the medical
oncologists and the surgeons. Because not all patients in study
had mixed venous partial pressure of oxygen or perfusion scans,
we calculated predicted postoperative pulmonary function by
quantifying the number of bronchopulmonary segments resected
to use the same methodology on all patients.
Dr Frank A. Baciewicz (Detroit, Mich). I have 1 quick
comment.
We recently studied a cohort of patients with forced expiratory
volume in 1 second around 1 L. We gave them several weeks ofrdiovascular Surgery c Volume 147, Number 2 745
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forced expiratory volume in 1 second. You don’t improve it
significantly and it doesn’t change their outcomes. This is data
we are publishing in the future.
I agree that the criteria mentioned do not define high-risk
patients. I was curious about patient outcomes if you subdivided746 The Journal of Thoracic and Cardiovascular Surgthem into patients who were receiving home oxygen or who had
forced expiratory volume in 1 second of 1 or<1.
Dr Taylor. We did not perform a subgroup analysis by
stratifying forced expiratory volume in 1 second of 1 or <1.
However, the use of preoperative oxygen therapy was not found
to be an independent predictor of death or major morbidity.ery c February 2014
